Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
PAVM
PAVM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PAVM News
PAVmed Reports Q4 2025 Financial Results with Key Metrics
13h ago
seekingalpha
PAVmed Restructures Capital and Relaunches Product Line
13h ago
PRnewswire
Lucid Diagnostics Reports Q4 Highlights and Revenue Growth
4d ago
PRnewswire
PAVmed to Announce Q4 Earnings on March 30
5d ago
seekingalpha
PAVmed to Host Business Update Conference Call
Mar 16 2026
PRnewswire
PAVmed to Host Business Update Conference Call
Mar 16 2026
Newsfilter
Lucid Diagnostics to Host Business Update Conference Call
Mar 12 2026
Newsfilter
PAVmed Secures $30 Million in Series D Preferred Stock Offering
Feb 04 2026
PRnewswire
PAVmed Subsidiary Secures VA Contract for EsoGuard Test, Expanding Access to Over 9 Million Veterans
Jan 22 2026
Benzinga
Lucid Diagnostics Secures VA Contract for EsoGuard, Boosting PAVmed Stock by 291%
Jan 21 2026
Benzinga
PAVmed Subsidiary Wins VA Contract for Esophageal Precancer Testing, Shares Surge 250%
Jan 21 2026
stocktwits
Netflix, Inc. (NFLX) Reports Q4 Earnings Beat but Issues Lower Q1 Guidance, Shares Down 3%
Jan 21 2026
Benzinga
Lucid Diagnostics (LUCD) Secures VA Contract for EsoGuard Esophageal DNA Test at Medicare Pricing
Jan 21 2026
seekingalpha
Lucid Diagnostics Secures VA Contract for EsoGuard Test, Expanding Access to 9 Million Veterans
Jan 21 2026
Newsfilter
PAVmed Executes 1-for-30 Reverse Stock Split to Maintain Nasdaq Listing
Dec 30 2025
PRnewswire
PAVmed Executes 1-for-30 Reverse Stock Split to Maintain Nasdaq Listing
Dec 30 2025
Newsfilter
Show More News
